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Abstract 30 
Background and aims 31 
It has been suggested that retinal lutein may improve visual acuity for images that are 32 
illuminated by white light. Our aim was to determine the effect of a lutein and antioxidant dietary 33 
supplement on visual function. 34 
Methods 35 
A prospective, nine- and eighteen-month, double-masked randomised controlled trial. For the 36 
nine-month trial, 46 healthy participants were randomised (using a random number generator) 37 
to placebo (n = 25) or active (n = 21) groups. Twenty-nine of these subjects went on to 38 
complete 18 months of supplementation, 15 from the placebo group, and 14 from the active 39 
group. The active group supplemented daily with 6 mg lutein combined with zinc and 40 
antioxidants. Outcome measures were distance and near visual acuity, contrast sensitivity, and 41 
photostress recovery time. The study had 80 % power at the 5 % significance level for each 42 
outcome measure. Data were collected at baseline, nine, and 18 months. 43 
Results 44 
There were no statistically significant differences between groups for any of the outcome 45 
measures over nine or 18 months.  46 
Conclusion 47 
There was no evidence of effect of nine or 18 months of daily supplementation with 6 mg lutein 48 
combined with zinc and antioxidants on visual function in this group of people with healthy eyes. 49 
ISRCTN78467674. 50 
 51 
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Introduction 59 
The role of lutein supplementation in the improvement in visual function for patients with age-60 
related macular degeneration (AMD) has been established via a randomised controlled trial 
1
. It 61 
has been suggested that lutein and its isomers, zeaxanthin and meso-zeaxanthin play a similar 62 
role in humans as in plants, as antioxidants and screeners of high-energy blue light 
2
.  63 
 64 
With respect to healthy eyes, the blue-light filter effect of lutein/zeaxanthin may reduce 65 
longitudinal chromatic aberration 
3-5
.
 
In addition, the acuity hypothesis states that these nutrients 66 
may improve visual acuity for images that are illuminated with white light by absorbing poorly 67 
focussed short wavelengths before this light is processed by the retina 
6, 7
. In theory, if an 68 
emmetropic eye views a mid-wavelength object (approximately 550 nm) in blue-dominated 69 
sunlight, shorter wavelengths will focus in front of the retina, and longer wavelengths will focus 70 
behind such that there is a range of focus of approximately 1.20 dioptres 
5
. The fact that images 71 
are not degraded may be explained in part by the pre-retinal filtering effect of the 72 
lutein/zeaxanthin. Lutein and its isomers are collectively known as macular pigment (MP) within 73 
the retina. 74 
 75 
During the design of the trial, 6 mg daily intake of lutein from food had been reported to be 76 
associated with a reduced risk of AMD (57 % lower risk for the highest quintile of lutein intake, 6 77 
mg per day, relative to the lowest quintile, 0.5 mg per day) 
8
. The reasons for using a multi-78 
ingredient formulation include the fact that AMD has a multifactorial aetiology, and so may be 79 
affected by more than one nutrient, and also that nutrients are thought to work synergistically 80 
together.  81 
 82 
Despite a lack of empirical evidence, lutein/zeaxanthin supplements are being taken by the 83 
public in an attempt to improve retinal health and vision in the absence of disease 
9
.The aim of 84 
this RCT was to determine the effect of a lutein and antioxidant dietary on measures of visual 85 
function in healthy eyes.  86 
 87 
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Materials and methods 88 
The study was approved by the Aston University Human Sciences Ethical Committee (code 89 
02/M). The tenets of the Declaration of Helsinki were followed 
10
. The trial was registered for an 90 
International Standard Randomised Controlled Trial Number (ISRCTN 78467674), and the 91 
method has been published 
11
. Reporting of this RCT adheres to the guidelines set out in the 92 
revised CONSORT statement 
12
. 93 
 94 
Recruitment 95 
Recruitment methods included an editorial in the regional press and advertising throughout the 96 
Aston University Campus. 97 
 98 
Research centres 99 
The main research centre was Aston University, Birmingham. A secondary research centre was 100 
a UK optometric clinical practice. Data collection took place in standard consulting rooms at 101 
both centres. Investigators and participants were masked to group assignment. 102 
 103 
Inclusion/exclusion criteria 104 
For inclusion, participants had to 1) provide written informed consent, 2) be available to attend 105 
one of the research centres, 3) present with no ocular pathology in either eye. Absence of 106 
pathology was assessed through dilated pupils using slit lamp binocular indirect 107 
ophthalmoscopy. Exclusion criteria relate to the inclusion of zinc and vitamin E in the study 108 
formulation. The exclusion criteria included type I and II diabetes as diabetic retinopathy may 109 
confound the results. Those taking anti-platelet or anti-coagulant medication were excluded 110 
because of possible interaction with vitamin E, as were those who used nutritional supplements 111 
that potentially raised vitamin and mineral intake above the recommended safe limits. People 112 
with conditions that affect dietary absorption, such as Crohn’s disease, were also excluded. 113 
 114 
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A dilated fundus examination was carried out prior to enrolment. Fundus photographs were 115 
taken using Topcon non-mydriatic TRC-NW5S retinal camera (Topcon House, Bone Lane, 116 
Kennet Side, Newbury, Berkshire RG14 2PX, UK) at baseline and at each subsequent visit. 117 
 118 
Masking 119 
The study formulation and placebo tablets were produced by Quest Vitamins Ltd, and were 120 
identical in external and internal appearance, and taste. The manufacturer allocated 121 
distinguishing symbols, μ and λ to the tablet containers. The trial was double-masked; and the 122 
manufacturer revealed the code only when all data had been collected and analysed. 123 
Throughout this manuscript, the letters P and A will be used to refer to the placebo and active 124 
formulation respectively.  125 
 126 
Intervention 127 
The study formulation contained the following: 128 
Lutein    6mg 129 
Vitamin A   750μg 130 
Vitamin C   250mg 131 
Vitamin E   34mg 132 
Zinc    10mg 133 
Copper    0.5mg 134 
The placebo tablets contained cellulose and were identical in appearance to the active tablets. 135 
 136 
Participants in both groups were instructed to take one tablet, at the same time every day, with 137 
food. They were encouraged not to alter their diets, or to change their current supplementation 138 
regime. A contact telephone number was provided. 139 
 140 
Randomisation 141 
Only one investigator was involved in the randomisation process, which employed the random-142 
number generator in Microsoft Excel for Windows XP. Odd and even numbers indicated group.  143 
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Outcome measures 144 
At the first visit, refractive error was neutralised with lenses for both eyes, and the eye with the 145 
best logMAR (minimum angle of resolution) score for visual acuity was included in the study. 146 
Only one eye of each participant was included. Refractive error was neutralised with lenses at 147 
each subsequent visit and the resulting trial lenses were used for all visual function tests. 148 
Distance visual acuity (DVA) was measured using Early-Treatment Diabetic Retinopathy Study 149 
(EDTRS) logMAR charts and near visual acuity (NVA) was measured using Bailey-Lovie 150 
reading cards. 151 
 152 
Contrast sensitivity (CS) provides additional information about vision and was measured using a 153 
Pelli-Robson chart (Clement Clarke International, Edinburgh Way, Harlow, Essex, CM20 2TT, 154 
UK). The Pelli-Robson chart determines the contrast required to read large letters and is 155 
designed to test mid- to low-spatial frequencies 
13
. 156 
 157 
The Eger Macular Stressometer (EMS) (Gulden Ophthalmics, Elkins Park, PA 19027) was used 158 
to measure photostress recovery time (PSRT). This is the time taken for the regeneration of 159 
photopigments in bleached photoreceptors to a level that allows resolution of, for example, a 160 
letter at near. The EMS has been found to be reliable to within ± 7 seconds 
14
. The instrument is 161 
hand-held and consists of a flash bulb and a near reading chart. It houses a 40.6 cm length of 162 
string, which, when extended, maintains a constant working distance while the subject 163 
determines the smallest letter size that can be read on the integrated VA chart monocularly. The 164 
test types range from Snellen equivalents of 6/6 to 6/30, with letter size decreasing from the top 165 
to the bottom of the chart. The working distance is then reduced to 15.2 cm (measured using a 166 
marker on the string) and the patient is directed to look at the centre of the flash tube, situated 167 
just above the test type. A third button press simultaneously activates the flash and starts the 168 
timer. The device is then returned to 40.6 cm and the patient is asked to read the line of letters 169 
above the smallest line read before bleaching as soon as it becomes visible. A fourth button 170 
press stops the timer when the patient has recovered enough macular function to correctly 171 
  Page 7 of 24
  
   
identify three from the five letters on the designated line. A note of this PSRT is made and a fifth 172 
press of the button resets the instrument. 173 
Sample size calculation 174 
Reliability data from previous studies was used to determine effect sizes for use in sample size 175 
calculations for visual acuity (± 0.1 logMAR) 
15
, CS (± 0.15 log units) 
13
, and PSRT ( ± 7 176 
seconds) 
14
. The largest group size required for 80% power at the 5% significance level was for 177 
DVA (n = 13), indicating that a total minimum of 26 participants was required for the study.  178 
 179 
Follow up  180 
Data collection took place at baseline, nine, and 18 months. Recruitment started in December 181 
2002 and ended in March 2004.  182 
 183 
Statistical analysis 184 
For each outcome measure the change between baseline, nine month, and 18-month values 185 
was calculated. Each data set was checked for normality of distribution using SPSS software 186 
(version 11) for Microsoft Windows XP. When the data set was normally distributed, a two-tailed 187 
independent samples t-test was used to determine whether the means of these values differed 188 
at the 5% significance level between the placebo and antioxidant formulation. When the data 189 
set was not normally distributed, the non-parametric Mann-Whitney U test was used. A mixed 190 
ANOVA was used to assess the effect of the between-subjects variable (group), and the within-191 
subjects variable (time), on the outcome measures (dependent variable).  192 
 193 
Enrolment, duration and compliance 194 
Out of the 66 people that completed enrolment questionnaires, eight did not meet the inclusion 195 
criteria or decided not to enrol. The remaining 58 individuals were randomised to active or 196 
placebo groups: a breakdown is shown the Consort flowchart (figure 1). 197 
 198 
Insert figure 1 about here. 199 
 200 
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Enrolment continued until nine months before the end of the data collection period, and this 201 
accounts for the difference in numbers between the nine- and 18-month cohorts. Of the 12 202 
participants that were lost to follow up, one became pregnant, two moved out of the area, four 203 
had difficulty taking the tablets, and five developed illnesses unrelated to the project. These 204 
subjects were not included for analysis. Of the 46 participants who took part for nine months, 29 205 
went on to take part for 18 months. 206 
 207 
Statistical analysis was carried out on a per protocol basis. Compliance was assessed by 208 
counting remaining tablets at the follow-up visits, and averaged 92.3 %. The difference in 209 
compliance was not significant for either cohort. 210 
 211 
Baseline data 212 
Although it is not usually considered necessary  to test for statistical differences between two 213 
randomly allocated groups, since any differences will have arisen by chance alone, we 214 
acknowledge that our small sample size could have  resulted in some baseline differences 215 
between groups. The cohort ranged in age from 22 to 73 years (mean ± SD: 50.0 ± 15.9), and 216 
seventy-four percent were female. For the nine-month trial, twenty-five participants were 217 
randomised to the placebo (mean ± SD age: 50.1 ± 15.1 years) and 21 (mean ± SD age: 49.8 ± 218 
16.4 years) to the active group. For the 18-month trial, 15 subjects were randomised to the 219 
placebo (mean ± SD age: 48.3 ± 15.8 years) and 14 to the active group (mean ± SD age: 46.7 ± 220 
16.0). There was no significant difference in age or gender between groups for the nine-month 221 
comparison. For the 18-month comparison, the P group contained two males and 13 females 222 
and the A group contained seven males and seven females (Χ
2
 = 4.71, p = 0.03); there was no 223 
significant difference in age. 224 
 225 
All participants were White British. There was no significant difference in eye colour or baseline 226 
DVA, NVA, CS, or EMS scores between groups. A Student’s t-test was used to assess 227 
differences between groups in age, smoking history (pack years), and years spent living abroad. 228 
Dietary intake of lutein, vitamins C and E, retinol equivalents, and zinc was assessed using food 229 
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frequency questionnaires and food diaries. Analysis of food diaries was carried out using 230 
FoodBase 2000 (Institute of Brain Chemistry and Human Nutrition, London) for Microsoft 231 
Windows XP. There was no significant difference between groups for any of these 232 
characteristics. In the A group, one person was taking thyroxine and one person was taking 233 
codeine. In the P group, one person was taking diazepam, one was taking thyroxine, and one 234 
was taking bendrofluazide. Participants were asked to provide details of additional nutritional 235 
supplementation. There was no difference in supplementation between groups (see table 1). 236 
 237 
Insert table 1 about here. 238 
 239 
The baseline characteristics are shown in table 2 for the nine-month group, and table 3 for the 240 
18-month group. 241 
Insert tables 2 and 3 about here 242 
 243 
Assessment of change in characteristics 244 
All participants were asked to fill out end-of-trial food diaries and food frequency questionnaires 245 
in order to assess any change in dietary habits over the trial period. Eighty percent were 246 
returned by the nine and 18-month P groups, 86 % by the nine month A group, and 79 % by the 247 
18 month A group.  248 
 249 
There was no change in dietary lutein, vitamin C, vitamin, E, or vitamin A for any of the groups 250 
(9P, 9A, 18P, or 18A). The normal nine month P group, however, had a significant change in 251 
mean zinc intake from (mean ± SD) 6.82 ± 2.15 mg to 10.26 ± 4.39 mg (t = -3.54, df = 24, p = 252 
0.002). There was no significant change in dietary zinc over time for any other group. There 253 
were no changes in ocular health or smoking habits, and no participants developed AMD-254 
related ocular changes.  255 
 256 
Adverse effects  257 
There were no reported adverse events or side effects from any of the study participants. 258 
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Results 259 
Masking success 260 
An end of trial, assessment was made of masking success by asking participants if they thought 261 
they knew which tablet they were taking, and if so, which one. Out of those participants taking 262 
the placebo tablet, 12 % correctly guessed which tablet they were taking, and 10 % incorrectly 263 
guessed. Out of those taking the nutritional supplement, 9 % guessed correctly which tablet 264 
they were taking, and 11% incorrectly guessed. The remaining participants were not prepared 265 
to make a guess indicating masking success. 266 
 267 
 268 
Outcomes: between groups 269 
There was no significant difference between groups at nine or 18 months for any of the outcome 270 
measures. Results are shown in tables 4 and 5, where the p value refers to the analysis of the 271 
difference in the amount of change between active and placebo groups for each outcome 272 
measure. 273 
 274 
Insert tables 4 and 5 about here. 275 
 276 
Outcomes: within groups 277 
In order to assess the effect of time on the outcome measures over nine months, paired 278 
samples t-tests were carried out for DVA, NVA, CS, and EMS score. There were significant 279 
improvements over nine months in DVA (p = 0.047, eta squared = 0.15), and NVA (p = 0.007, 280 
eta squared = 0.27) in the P group. Eta squared describes the effect size and the following 281 
guidelines can be used for interpretation: 0.01 = small effect, 0.06 = moderate effect, 0.14 = 282 
large effect. Although the eta squared values for DVA and NVA suggest a large effect these 283 
changes are not clinically significant, 
15
. 284 
 285 
For those participants who attended two follow-up visits, a mixed between-within subjects 286 
ANOVA was carried out to determine whether there was a change in each outcome measure 287 
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over time (main effect for time), if there was a difference in the effect on each outcome measure 288 
between the two interventions (main effect for group), and also whether there is the same 289 
change in scores over time for the two groups (interaction effect). The ANOVA results are 290 
shown in table 6 and the change in outcome measures over 18 months are shown graphically in 291 
figures 2 to 5. 292 
 293 
Insert table 6 and figures 2 to 5 about here. 294 
 295 
There was a significant change in CS and EMS score over time, but there was no difference 296 
between the P and A groups, and no difference in the change in these outcome measures over 297 
time between the two groups. The effect size for the change over time was moderate for CS 298 
(Eta squared = 0.119) and large for the EMS (Eta squared = 0.149). In the A group, the 299 
changes were not clinically significant for CS (less than ± 0.15 log units) 
13
 or EMS (less than ± 300 
7 seconds) 
14
. In the P group, the change in EMS was not clinically significant but the change in 301 
CS of + 0.15 log units is the limit for clinical significance. Apart from chance, the only 302 
explanation for this change in CS is that the scores did in fact improve in the P group over time. 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
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Discussion 317 
This clinical trial was designed to evaluate the effect of a nutritional supplement containing 6mg 318 
lutein, 750 μg vitamin A, 250 mg vitamin C, 34 mg vitamin E, 10 mg zinc, and 0.5 mg copper on 319 
clinical measures of visual function. The study demonstrated that this nutritional supplement 320 
had no effect on clinical visual outcome measures over nine or 18 months in healthy eyes. The 321 
same formulation was assessed in a randomised control trial of people with age-related 322 
maculopathy, which was powered for CS as an outcome measure 
16
. The formulation had no 323 
significant effect in this group either. Other combined-nutrient formulations have been effective 324 
in improving visual function for people with age-related macular disease, including those used in 325 
the Age-Related Eye Disease Study (AREDS) 
17
 and the Lutein Antioxidant Supplementation 326 
trial (LAST) 
1
. A full review of randomised controlled trials investigating the effect of nutritional 327 
supplementation on age-related macular disease has been published by the authors 
18
. 328 
 329 
A branch of the AREDS looked at the effect of antioxidant and zinc supplementation on visual 330 
loss in people with age-related cataract and found no significant effect 
19
. Conversely, in another 331 
randomised controlled trial, supplementation with 15 mg of lutein three times per week for two 332 
years was associated with improvements in visual acuity and glare sensitivity in patients with 333 
age-related cataract. However, no effect was found using 100 mg alpha-tocopherol 334 
supplementation three times weekly 
20
.  335 
 336 
In a healthy group of 27 subjects aged between 60 and 84 years, those with higher levels of MP 337 
did not have significantly different visual sensitivity than a group of younger subjects aged 338 
between 24 and 36 years, whereas subjects in the older group with lower levels of MP did differ 339 
from the younger group 
21
. This suggests that retinal lutein levels may effect visual function.  340 
 341 
The specific uptake of lutein and zeaxanthin at the macula has been investigated with respect to 342 
the potential functional role of these carotenoids in normal visual function. The macula is 343 
specialized for high spatial resolution and also for colour vision and it has been hypothesised 344 
that lutein and zeaxanthin play a part in these processes. With any optical system defects in the 345 
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formation of the image occur and these aberrations can be classified as chromatic or 346 
monochromatic. In the human eye longitudinal chromatic aberration results from the dispersion 347 
characteristics of the ocular media, and a dioptric interval of around 0.9 D between the paraxial 348 
foci for 656.3 nm red light and 486.1 nm blue light has been reported 
22
. Transverse chromatic 349 
aberration results in long-wavelength light being deviated less than short-wavelength light, 350 
which has the effect of producing a red blur around the edge of an image. When viewing white 351 
light, the combined effect of transverse and longitudinal chromatic aberration would be to create 352 
a purple penumbra, or shadow, to the image.  353 
 354 
Short-wavelength light is scattered more than long-wavelength light by air molecules and larger 355 
atmospheric molecules. This scattering effect results in the blue coloration of the sky, as well as 356 
the blue haze seen around objects viewed in the distance. Wooten and Hammond 
7
 hypothesize 357 
that MP may increase visibility by reducing the luminance of the background with respect to the 358 
object itself. This means that the contrast of the object is increased.  A person with a macular 359 
pigment optical density (MPOD, the amount of lutein or its isomers at any point in the retina) of 360 
0.0 would only be able to see an object at 10 km that a person with an MPOD of 0.5 would be 361 
able to see at 11.9 km. 362 
 363 
In 1866 it was proposed that MP might reduce longitudinal chromatic aberration through 364 
absorption of short-wavelength light 
23
. It has been since been shown that a filter covering a 365 
similar spectral range to MP can reduce the radiance of the short-wavelength blur circle to a 366 
sub-threshold value 
24
. The hypothesis that MP reduces short-wavelength chromatic blur and 367 
therefore enhances spatial vision (often termed the acuity hypothesis) 
7
 has been tested under 368 
different illumination conditions. One condition consisted of mid-wavelength yellow light that is 369 
not absorbed by MP, and the other consisted of a white light that was subject to chromatic 370 
aberration because the blue portion would be absorbed by MP 
25
. No relationship between MP 371 
and resolution acuity or between MP and hyperacuity in either illumination condition was found. 372 
However, a marginal improvement in red-green discrimination with increased MPOD has been 373 
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reported, supporting the theory that increasing MP levels improves human chromatic 374 
discrimination sensitivity 
26
.  375 
 376 
Macular pigment is also thought to improve visual performance by reducing the strength of the 377 
rod signals that are subject to large spatial summation and therefore more sluggish responses 378 
27
. Absorption of blue light by MP may extend high-acuity cone-mediated vision at low light 379 
levels. Supplementation with 10 or 20 mg daily lutein or zeaxanthin over six months was 380 
reported to lower contrast acuity thresholds in the mesopic range in a recent conference 381 
abstract 
27
. Similarly, a significant downward trend in contrast acuity thresholds was found with 382 
10 mg or 20 mg daily lutein and zeaxanthin supplementation in a larger cohort, although MPOD 383 
was not significantly correlated with either the amount of forward light scatter in the eye, or 384 
contrast acuity thresholds 
28
. 385 
 386 
Conflict in the literature may be explained by the acuity hypothesis. Although the MP filters the 387 
out-of-focus short wavelength light, there is an associated reduction in luminance that may 388 
effect acuity 
29
. In other words, any improvement in visual acuity may be countered by 389 
luminance reduction. 390 
 391 
Studies investigating retinal response (as opposed to serum response) to lutein 392 
supplementation have found a range of responses, including no retinal response in three out of 393 
11 people over 14 weeks 
30
, and no retinal response overall in a cohort of 12 young and 17 394 
elderly subjects following 5 weeks of supplementation 
31
. .Increases in MPOD of 15 – 23 % 395 
have been found in some studies 
32-34
, while increases of around 40 % have been reported in 396 
others 
1, 35-37
. 397 
 398 
A putative lutein-binding protein which binds with high affinity and specificity to lutein and other 399 
xanthophylls has been discovered in the retinae of human eyes 
38
, It has been suggested that 400 
people who are less responsive to lutein supplementation may be so because of genetic 401 
differences that result in reduced or less efficient binding proteins 
39
. It is possible that this factor 402 
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may have had an effect on our results but we believe it is unlikely that all participants would 403 
have been non-responders.  404 
 405 
The fact that MPOD was not measured in this study means that we do not know how 406 
responsive the participants were to the lutein supplementation. It would also have been 407 
interesting to track MP levels over the nine and eighteen month intervention periods. 408 
Unfortunately we did not have access to an MPOD measurement device at the start of the trial.  409 
 410 
Studies have been carried out to investigate differences in bioavailability between pure and 411 
esterified lutein. One study reported no significant difference in serum lutein response between 412 
6 mg lutein from spinach, 6 mg pure lutein, and 10.23 mg lutein esters 
40
. In another study, 413 
serum response was greater from lutein esters than pure lutein 
41
. Although these studies 414 
suggest that the use of lutein esters in our formulation should not have hindered bioavailability, 415 
it is important to note that they recorded serum response rather than retinal response. Although 416 
the retinal response is related to serum response, and dietary modification affects both, there is 417 
some variability in retinal response between subjects 
30, 32, 42
.  418 
 419 
The use of a mixed antioxidant and mineral formulation does not permit assessment of the 420 
effect of specific nutrients on visual function. The rationale for using a mixed formulation is that 421 
nutrients are thought to work synergistically together. A relevant example of this synergism is 422 
the facilitation of vitamin A transport from the liver by zinc 
43
. Although serum concentrations of 423 
lutein, zeaxanthin and antioxidants have been found to be responsive to dietary modifications 
30, 
424 
36
, they were not measured during this trial. Non-invasive compliance assessment was 425 
undertaken as blood analysis was considered likely to hinder recruitment. 426 
 427 
At baseline the nine-month P group consumed significantly more dietary vitamin C than the A 428 
group. End of trial dietary analysis was carried out on at least 75 % of the participants in each 429 
group. There was no change with time in dietary lutein, vitamins C and E, and retinol 430 
equivalents in any of the groups. A mean increase in dietary zinc intake was shown in the nine 431 
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month P group. These differences could confound the results, although this would be of greater 432 
concern if a significant difference in improvement of any of the outcome measures had been 433 
found between the P and A groups in the nine-month cohort. 434 
 435 
The results of this study add to the debate within the literature. Nutritional supplementation that 436 
includes 10 mg lutein daily has been associated with improved visual function in people with 437 
AMD 
1
 and supplementation with 15 mg of lutein three times per week for two years was 438 
associated with improvements in visual acuity and glare sensitivity in patients with age-related 439 
cataract 
20
. A significant trend for improvement in CS was found with 10 mg or 20 mg daily lutein 440 
and zeaxanthin supplementation in people with healthy eyes 
28
. The results of this study 441 
suggest that daily supplementation with 6 mg lutein combined with zinc and antioxidants is not 442 
sufficient to effect a change in visual function. The results of other studies suggest that daily 443 
supplementation with at least 10 mg of lutein may result an improvement in visual function in 444 
people with age-related macular disease, age-related cataract, or healthy eyes. Lutein dosage 445 
may be an important factor in the effectiveness of ocular nutritional supplements. 446 
 447 
 448 
 449 
 450 
 451 
 452 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
 460 
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Figure legends 619 
Figure 1: CONSORT flow diagram 620 
Figure 2: Mean distance visual acuity (DVA) recorded for the 18 month cohort at baseline, nine, 621 
and eighteen months. Error bars represent standard deviation. 622 
Figure 3: Mean near visual acuity (NVA) recorded for the 18 month cohort at baseline, nine, and 623 
eighteen months. Error bars represent standard deviation. 624 
Figure 4: Mean contrast sensitivity (CS) recorded for the 18 month cohort at baseline, nine, and 625 
eighteen months. Error bars represent standard deviation. 626 
Figure 5: Mean Eger macular stressometer (EMS) score recorded for the 18 month cohort at 627 
baseline, nine, and eighteen months. Error bars represent standard deviation. 628 
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